A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
PURPOSE: This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory metastatic colorectal cancer. METHODS: The first stage of this study was a standard "3 + 3" open-label dose-escalation scheme. Cohorts of 3-6 subjects were started with 120 mg of regorafenib given PO daily for 3 weeks of a 4 week cycle, plus 4.5 mg/kg of PF-03446962 given IV every 2 weeks. Doses of both drugs were adjusted according to dose-limiting toxicities (DLT). Plasma was collected for multiplexed ELISA analysis of factors related to tumor growth and angiogenesis. RESULTS: Seventeen subjects were enrolled, of whom 11 were deemed evaluable. Seven subjects were enrolled at dose level 1, and four were enrolled at level - 1. Overall, three DLTs were observed during the dose-escalation phase: two in level 1 and one in level - 1. A planned dose-expansion cohort was not started due to early termination of the clinical trial. Common adverse events were infusion-related reaction, fatigue, palmar-plantar erythrodysesthesia syndrome, abdominal pain, dehydration, nausea, back pain, anorexia, and diarrhea. One subject achieved stable disease for 5.5 months, but discontinued treatment due to adverse events. CONCLUSIONS: The regimen of regorafenib and PF-03446962 was associated with unacceptable toxicity and did not demonstrate notable clinical activity in patients with refractory metastatic colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in a Phase Ib trial study, regorafenib combined with PF-03446962 did not show significant clinical activity in patients with refractory mCRC [81].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Lymphangiogenesis in development and human disease
Alitalo, K., Tammela, T., & Petrova, T. V. (2005) · Nature · doi:10.1038/nature04480 · Cited by 1,285
Park, J. E., Chen, H. H., Winer, J., Houck, K. A., & Ferrara, N. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47298-5 · Cited by 1,112
ALK1 as an emerging target for antiangiogenic therapy of cancer.
Cunha, S. I., & Pietras, K. (2011) · Blood · doi:10.1182/blood-2011-01-330142 · Cited by 184
Fonsatti, E., Nicolay, H. J. M., Altomonte, M., Covre, A., & Maio, M. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvp332 · Cited by 165
Hawighorst, T., Velasco, P., Streit, M., Hong, Y., Kyriakides, T. R., Brown, L. F., Bornstein, P., & Detmar, M. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.11.2631 · Cited by 148
Hu-Lowe, D. D., Chen, E., Zhang, L., Watson, K. D., Mancuso, P., Lappin, P., Wickman, G., Chen, J. H., Wang, J., Jiang, X., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1451 · Cited by 130
Lieu, C. H., Tran, H., Jiang, Z.-Q., Mao, M., Overman, M. J., Lin, E., Eng, C., Morris, J., Ellis, L., Heymach, J. V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077117 · Cited by 127
Duffy, A. G., Ma, C., Ulahannan, S. V., Rahma, O. E., Makarova-Rusher, O., Cao, L., Yu, Y., Kleiner, D. E., Trepel, J., Lee, M.-J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3171 · Cited by 80
Cited by
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
Ciardiello, D., Elez, E., Tabernero, J., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 265
Metadata
- Authors
- Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., Niedzwiecki, D., Watson, H., Bolch, E., Arrowood, C., Liu, Y., Nixon, A. B., & Hurwitz, H. I.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- Genentech (US)
- Corresponding author
- Clarke, Jeffrey Melson
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2019-08-23
- Volume
- 84
- Issue
- 4
- Pages
- 909-917
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC6769092
- OpenAlex
- W2969718979
- Cited by
- 18
- References
- 20
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 6
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pfizer (WI178914)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- regorafenib, metastatic colorectal cancer, combination therapy, dose-limiting toxicity, maximum tolerated dose, angiogenesis, tumor growth factors, drug safety and tolerability
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Neoplasm Staging, Phenylurea Compounds, Pyridines, Colorectal Neoplasms, Drug Monitoring, Maximum Tolerated Dose, Activin Receptors, Type II, Early Termination of Clinical Trials, Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). https://app.cochat.ai/papers/10.1007/s00280-019-03916-0
- The paper
- Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., Niedzwiecki, D., Watson, H., Bolch, E., Arrowood, C., Liu, Y., Nixon, A. B., & Hurwitz, H. I. (2019). A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-019-03916-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.